Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Questions Raised Over Revlimid Safety

By Drug Discovery Trends Editor | December 6, 2010

Shares of Celgene Corp. tumbled Monday morning as analysts dissected concerns raised by data presented for the biotech drugmaker’s Revlimid cancer treatment at the American Society of Hematology meeting.

A clinical trial investigator said more occurrences of observed secondary malignancies have been found in patients who received a maintenance dose of the myeloma treatment compared to those who received a placebo. Jefferies & Co. analyst Thomas Wei said in a research note company officials believe the rate falls within historical rates for myeloma patients.

Revlimid is a pill taken for multiple myeloma, a type of blood cancer. It is approved in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid sales rose 43 percent in the third quarter to $641 million.

That represented 70 percent of Celgene’s total revenue of $910.1 million in the quarter.

Baird analyst Christopher J. Raymond said in a separate research note that while the possibility of secondary malignancies may “raise a few eyebrows, we think this signal is completely explainable and would use any weakness in the stock as a buying opportunity.” Raymond said the drug’s safety is worth watching, but saw nothing to change the firm’s thesis on the company.

Baird has an “outperform” rating on the stock.

Wei said Jefferies continues to believe “Revlimid maintenance could become part of the gold standard treatment strategy for front-line myeloma.”

Date: December 6, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE